TY - JOUR
T1 - Advanced in vitro models for renal cell carcinoma therapy design
AU - Mieville, Valentin
AU - Griffioen, Arjan W.
AU - Benamran, Daniel
AU - Nowak-Sliwinska, Patrycja
N1 - Funding Information: This work was supported by the Geneva Cancer League [2005, 2020, to PNS]; and Foundation Ernest Boninchi [ 102740 , 2021, to PNS]. Publisher Copyright: © 2023 The Authors
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Renal cell carcinoma (RCC) and its principal subtype, clear cell RCC, are the most diagnosed kidney cancer. Despite substantial improvement over the last decades, current pharmacological intervention still fails to achieve long-term therapeutic success. RCC is characterized by a high intra- and inter-tumoral heterogeneity and is heavily influenced by the crosstalk of the cells composing the tumor microenvironment, such as cancer-associated fibroblasts, endothelial cells and immune cells. Moreover, multiple physicochemical properties such as pH, interstitial pressure or oxygenation may also play an important role. These elements are often poorly recapitulated in in vitro models used for drug development. This inadequate recapitulation of the tumor is partially responsible for the current lack of an effective and curative treatment. Therefore, there are needs for more complex in vitro or ex vivo drug screening models. In this review, we discuss the current state-of-the-art of RCC models and suggest strategies for their further development.
AB - Renal cell carcinoma (RCC) and its principal subtype, clear cell RCC, are the most diagnosed kidney cancer. Despite substantial improvement over the last decades, current pharmacological intervention still fails to achieve long-term therapeutic success. RCC is characterized by a high intra- and inter-tumoral heterogeneity and is heavily influenced by the crosstalk of the cells composing the tumor microenvironment, such as cancer-associated fibroblasts, endothelial cells and immune cells. Moreover, multiple physicochemical properties such as pH, interstitial pressure or oxygenation may also play an important role. These elements are often poorly recapitulated in in vitro models used for drug development. This inadequate recapitulation of the tumor is partially responsible for the current lack of an effective and curative treatment. Therefore, there are needs for more complex in vitro or ex vivo drug screening models. In this review, we discuss the current state-of-the-art of RCC models and suggest strategies for their further development.
KW - Angiogenesis
KW - Cancer-associated fibroblasts
KW - Hypoxia
KW - Immune system
KW - Microfluidic device
KW - Organ-on-chip
KW - Organoids
KW - Renal cell carcinoma
KW - Screening platform
KW - Tumor microenvironment
KW - pH
UR - http://www.scopus.com/inward/record.url?scp=85163802964&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.bbcan.2023.188942
DO - https://doi.org/10.1016/j.bbcan.2023.188942
M3 - Review article
C2 - 37343729
SN - 0304-419X
VL - 1878
JO - Biochimica et Biophysica Acta - Reviews on Cancer
JF - Biochimica et Biophysica Acta - Reviews on Cancer
IS - 5
M1 - 188942
ER -